Olorinab

Olorinab
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name (4aS,5aS)-N-((2S)-1-Hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta[1,2-c]pyrazole-3-carboxamide;
CAS Number	1268881-20-4;
PubChem CID	60164925;
KEGG	D11429;
Chemical and physical data
Formula	C18H24N5O3
Molar mass	358.422 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-];
	InChI InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1; Key:ACSQLTBPYZSGBA-GMXVVIOVSA-N;

Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome.[1] It acts as a potent and selective cannabinoid CB₂ receptor agonist and is claimed to be orally active and peripherally selective.[2][3] Initial Phase IIa exploratory clinical trials have been successful,[4] with Phase IIb trials projected to start in 2019.[5]

References

"Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMC 5733264. PMID 29259753.
"Olorinab (APD371)". Arena Pharmaceuticals, Inc.
"Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
"18th Annual Needham Healthcare Conference". wsw.com. Retrieved 2019-04-13.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.

[pmid29259753-2] Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMC 5733264. PMID 29259753.

[3] "Olorinab (APD371)". Arena Pharmaceuticals, Inc.

[4] "Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.

[5] "18th Annual Needham Healthcare Conference". wsw.com. Retrieved 2019-04-13.

Olorinab

See also

References